



MAYNE PHARMA RESPONSE TO MEDIA SPECULATION

08 November 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX), ("Mayne Pharma") refers to the media speculation in Australian Financial Review's Street Talk published on 7 November 2024 regarding its appointment of Jefferies Australia.

Mayne Pharma confirms that Jefferies is its financial adviser and continues to support the Company in assessing its strategies for maximising shareholder value. Mayne Pharma will keep the market informed in accordance with its continuous disclosure obligations.

For further information contact:

Dr Tom Duthy
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit [maynepharma.com](https://www.maynepharma.com).